medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2019, Número 3

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2019; 35 (3)


SMILE en linfoma de células NK/T extranodal en recaída

Martínez ADR, Gracia ME, Martínez ELY, Medina PVM, Mir EYL

Idioma: Español
Referencias bibliográficas: 27
Paginas: 1-11
Archivo PDF: 316.32 Kb.


RESUMEN

Introducción: El linfoma extranodal de células NK/T, tipo nasal es una variedad agresiva que se presenta con mayor frecuencia en Asia Oriental y América Latina. El régimen de tratamiento SMILE, basado en dexametasona, metotrexato, ifosfamida, L-asparaginasa y etopósido, mostró tasas de respuestas objetivas adecuadas en estudios de fase 1/2. Objetivo: presentar el primer reporte de la aplicación del protocolo SMILE en Cuba. Presentación del caso: paciente de 47 años de edad, blanca que presentó recaída temprana de linfoma extranodal de células NK/T tipo nasal en partes blandas de la pared anterior izquierda del tórax. Recibió quimioterapia SMILE por 4 ciclos y en la evaluación al final del tratamiento se comprobó que hubo una respuesta completa de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M. Extranodal NK/T-cell lymphoma, nasal type (ENKTL-NT): An update on epidemiology, clinical presentation, and natural history in North American and European cases. Curr Hematol Malig Rep. 2016; 11(6): 514–27. DOI:10.1007/s11899-016-0355-9.

  2. Suzuki R. Pathogenesis and Treatment of Extranodal Natural Killer/T-Cell Lymphoma. SeminHematol.2014; 51: 42-51.

  3. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for a dvanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99(5):1016-20.

  4. Weiben Y, Wen Z, Yuntao Z, Jun Z,Yan W, Deliang Z, et al. L-asparaginase based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol.2003;78(2):163-7.

  5. Imashuku S1, Hibi S, Ohara T, Iwai A, Sako M, Kato M, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immune chemotherapy. HistiocyteSociety.Blood.1999;93(6):1869-74.

  6. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J ClinOncol.2011;29(33):4410-6.

  7. George LC1, Rowe M, Fox CP. Epstein-Barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved. Curr Hematol Malig Rep. 2012;7(4):276-84.

  8. Lanier L, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med. 1989; 169(6):2233-8.

  9. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013; 121(25): 4997-5005.

  10. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol. 2011;11(10):645–57.

  11. Montaldo E, Vacca P, Moretta L, Mingari MC. Development of human natural killer cells and other innate lymphoid cells. Semin Immunol. 2014; 26(2):107–13.

  12. Tse E, Kwong YL. Diagnosis and management of extranodal NK/T cell lymphoma nasal type. Expert Rev Hematol. 2016;9(9):861–71.

  13. Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol.2014; 164:536–45.

  14. Karkera AC, Parsons BM, Borgert A, Go RS. NK/T cell lymphoma in the U.S: A population-based study using the National Cancer Database from 1998–2012. J Clin Oncol. 2016; 34(15 Supl):e19038.

  15. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F,et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (Aspa-Met-Dexregimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood.2011;117:1834–9.

  16. Kreisel FH. Hematolymphoid Lesions of the Sinonasal Tract. Head Neck Pathol. 2016;10:109–17.

  17. Kidwai SM, Parasher AK, Lin FY. An unusual presentation of NK/T-cell lymphoma, nasal-type in the United States. Am J Otolaryngol.2015;36:80–3.

  18. Qi S, Yahalom J, Hsu M, Chelius M, Lunning M, Moskowitz A, et al. Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. Leuk Lymphoma. 2016 Nov;57(11):2575-83. doi: 10.1080/10428194.2016.1180689.

  19. Lima, M. Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis. Orphanet J Rare Dis 2013; 8: 95.doi: 10.1186/1750-1172-8-95.

  20. Yang Y, Zhu Y, Cao JZ, Zhang YJ, Xu LM, Yuan ZY, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood.2015; 126:1424–32.quiz 1517.

  21. Liu QF, Wang WH, Wang SL, Liu YP, Huang WT, Lu N, et al. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2014;88(4):806-13.

  22. Vazquez A, Khan MN, Blake DM, Sanghvi S, Baredes S, Eloy JA. Extranodal natural killer/T-cell lymphoma: a population-based comparison of sinonasal and extranasal disease. Laryngoscope. 2014;124(4):888-95.

  23. Deng T, Zhang C, Zhang X, Wu S, Xu Y, Liu S, et al. Treatment outcome of radiotherapy alone versus radiochemotherapy in IE/IIE extranodal nasal type natural killer/T cell lymphoma: a meta-analysis. PLoSOne. 2014;9(9):e106577.

  24. MatsumotoY, Nomura K, Kanda-Akano Y, Fujita Y, Nakao M, Ueda K, et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma. 2003;44:879–82.

  25. Jaccard A, Petit B,GiraultS, Suarez F, GressinR, Zini JM,et al. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol. 2009 Jan;20(1):110-6. DOI: 10.1093/annonc/mdn542.

  26. Lam Kwong Y, Seog Kim W, ThyeLim S, Jin Kim S, Tang T, Tse E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group Blood.2012;120:2973-80. DOI: 10.1182/blood-2012-05-431460

  27. Suzuki R. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma. Sem Hematol. 2014;51:42–51.




2020     |     www.medigraphic.com